Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Safety and Tolerability and Pharmacokinetic/Pharmacodynamic assessment of inflammation-related biomarkers.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Rheumatoid Arthritis on a stable dose of methotrexate
Rheumatoid Arthritis disease activity as assessed by blood tests
You may not be if
Serious or uncontrolled medical conditions
Current or recent treatment with disease-modifying drugs other than methotrexate including but not limited to leflunomide, sulfasalazine, etanercept, infliximab, adalimumab, abatacept, rituximab
Current oral glucocorticoid dose of more than 10 mg/d prednisone equivalent
Clareo Health | Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis
